letrozole and Dexametazon effect in Poly cystic ovarian syndrome patients
Phase 1
- Conditions
- polycystic ovarian syndrome.Polycystic ovarian syndrome
- Registration Number
- IRCT20170315033085N4
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 106
Inclusion Criteria
AGE: 25-35 years
at least one patent Fallopian tube
normal sperm analysis of spouse
presence of poly-cystic ovarian syndrome
Exclusion Criteria
Smoking
underlying disease ( heart, kidney, liver or Endocrine)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method uteinizing hormone. Timepoint: Third and 12th day of menstrual cycle. Method of measurement: laboratory Test.;Testestron. Timepoint: Third and 12th day of menstrual cycle. Method of measurement: laboratory Test.;Anderestandion. Timepoint: Third and 12th day of menstrual cycle. Method of measurement: laboratory Test.;Esteradiol. Timepoint: Third and 12th day of menstrual cycle. Method of measurement: laboratory Test.;Pregnancy. Timepoint: 14 days after Intrauterine insemination. Method of measurement: laboratory Test, pregnancy test.
- Secondary Outcome Measures
Name Time Method Dominant follicles. Timepoint: 12th day of Menestural cycle. Method of measurement: vaginal Sonography.;Endometrium thickness. Timepoint: 12th day of Menestural cycle. Method of measurement: vaginal Sonography.